IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4765 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
Read this article

 


    Article Cited by others

LETTER TO EDITOR

Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose

Pavithran Keechilat, Thomas Mathew

Year : 2005| Volume: 71| Issue : 4 | Page no: 288-289

   This article has been cited by
 
1 Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas (English Edition). 2014; 105(7): 655
[Pubmed]  [Google Scholar] [DOI]
2 Life-threatening dermatologic adverse events in oncology
Alyx C. Rosen,Yevgeniy Balagula,Dennis W. Raisch,Vishvas Garg,Beatrice Nardone,Nicole Larsen,Jennifer Sorrell,Dennis P. West,Milan J. Anadkat,Mario E. Lacouture
Anti-Cancer Drugs. 2014; 25(2): 225
[Pubmed]  [Google Scholar] [DOI]
3 Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
V. Brazzelli,V. Grasso,G. Borroni
Journal of the European Academy of Dermatology and Venereology. 2013; : n/a
[Pubmed]  [Google Scholar] [DOI]
4 Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)
M. Pretel-Irazabal,A. Tuneu-Valls,N. Ormaechea-Pérez
Actas Dermo-Sifiliográficas. 2013;
[Pubmed]  [Google Scholar] [DOI]
5 Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0
Alice P. Chen,Ann Setser,Milan J. Anadkat,Jonathan Cotliar,Elise A. Olsen,Benjamin C. Garden,Mario E. Lacouture
Journal of the American Academy of Dermatology. 2012; 67(5): 1025
[Pubmed]  [Google Scholar] [DOI]
6 Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Caroline Robert,Vincent Sibaud,Christine Mateus,Basil S. Cherpelis
Seminars in Oncology. 2012; 39(2): 227
[Pubmed]  [Google Scholar] [DOI]
7 Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib : Practical approach
IRIS AMITAY-LAISH, SALOMON M. STEMMER, MARIO E. LACOUTURE
Dermatologic Therapy. 2011; 24(4): 386
[HTML Full text]  [Google Scholar] [DOI]
8 Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia
Rishard Salie, Richard T. Silver
Clinical Lymphoma Myeloma & Leukemia. 2010; 10(5): 331
[HTML Full text]  [Google Scholar] [DOI]
9 Efectos secundarios cutáneos de los fármacos antineoplásicos (II): inhibidores de cinasas y anticuerpos monoclonales
Lorena Leal Canosa,María José Fuente González,Miquel Ribera Pibernat
Piel. 2009; 24(8): 427
[Pubmed]  [Google Scholar] [DOI]
10 Stevens-johnson syndrome induced by combination of imatinib and allopurinol
Hsieh, H.-J., Chan, A.L.F., Lin, S.-J.
Chemotherapy. 2009; 55(4): 197-199
[Pubmed]  [Google Scholar]
11 Secondary cutaneous effects of antineoplastic drugs (II): Kinase inhibitors and monoclonal antibodies | [Efectos secundarios cutáneos de los fármacos antineoplásicos (II): Inhibidores de cinasas y anticuerpos monoclonales]
Canosa, L.L., González, M.J.F., Pibernat, M.R.
Piel. 2009; 24(8): 427-439
[Pubmed]  [Google Scholar]
12 Therapeutic options for chronic myeloid leukemia: Focus on imatinib (Glivec®, Gleevec™)
Henkes, M., van der Kuip, H., Aulitzky, W.E.
Therapeutics and Clinical Risk Management. 2008; 4(1): 163-187
[Pubmed]  [Google Scholar]
13 Chemotherapeutic agents and the skin: An update
Heidary, N., Naik, H., Burgin, S.
Journal of the American Academy of Dermatology. 2008; 58(4): 545-570
[Pubmed]  [Google Scholar]
14 Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Alfonso Quintás-Cardama,Jorge E. Cortés,Hagop Kantarjian
Clinical Lymphoma and Myeloma. 2008; 8: S82
[Pubmed]  [Google Scholar] [DOI]
15 Chemotherapeutic agents and the skin: An update
Noushin Heidary,Haley Naik,Susan Burgin
Journal of the American Academy of Dermatology. 2008; 58(4): 545
[Pubmed]  [Google Scholar] [DOI]
16 Imatinib-induced Stevens-Johnson syndrome: Recurrence after re-challenge with a lower dose
Mahapatra M, Mishra P, Kumar R
Annals of Hematology. 2007; 86(7): 537-538
[Pubmed]  [Google Scholar]
17 Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose
Manoranjan Mahapatra,Pravas Mishra,Rajat Kumar
Annals of Hematology. 2007; 86(7): 537
[Pubmed]  [Google Scholar] [DOI]

 

Online since 15th March '04
Published by Wolters Kluwer - Medknow